New research has identified the enzyme glutamate dehydrogenase 1 (GLUD1) as a new therapeutic target for Duchenne muscular dystrophy (DMD). In preclinical DMD mouse models, investigators demonstrated ...

A preclinical study led by the Germans Trias i Pujol Research Institute (IGTP), in collaboration with the Institut de ...

Physical therapy supports Duchenne muscular dystrophy (DMD) care by maintaining strength and flexibility, improving movement, and lowering the risk of contractures. A physical therapist also monitors ...

Please provide your email address to receive an email when new articles are posted on . Interim results also showed reduction of the neurodegenerative biomarker neurofilament light chain. Serious ...

New research has identified the enzyme glutamate dehydrogenase 1 (GLUD1) as a new therapeutic target for Duchenne muscular dystrophy (DMD). In preclinical DMD mouse models, investigators demonstrated ...

The least-squares mean difference in the Hammersmith Functional Motor Scale-Expanded change from baseline at 12 months was 1.8 points for those 2 to 12 years receiving apitegromab vs placebo.

Researchers report that an experimental drug first developed to treat kidney disease prolongs survival and improves muscle function in mice genetically engineered to develop a severe form of Duchenne ...

Scientists from The University of Manchester and Northern Care Alliance NHS Foundation Trust have discovered that the ...

"Muscle health is having a moment." ...

You’re relaxing on the sofa when suddenly your eyelid starts twitching. Or perhaps it’s a muscle in your arm, your leg, or your foot that begins to spasm – sometimes for a few seconds, sometimes for ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. 30.4% of patients who received apitegromab had a 3-point ...